8-K: IN8bio Reports Q1 2026 Results, Advances T Cell Therapies

IN8bio announced first quarter 2026 financial results, highlighting progress in its gamma-delta T cell therapies and T cell engager platform, with encouraging glioblastoma data and upcoming R&D Day.

Summary

• IN8bio reported its financial results for the first quarter ended March 31, 2026.
• The company advanced its next-generation T cell engager (TCE) platform, INB-619, showing preclinical data with complete B cell depletion and minimal cytokine release syndrome (CRS).
• Encouraging data from Phase 1 (INB-200) and Phase 2 (INB-400) trials for DeltEx drug resistant immunotherapy (DRI) gamma-delta T cells in newly diagnosed glioblastoma (GBM) showed a 97% improvement in progression-free survival (PFS) compared to standard-of-care (SOC).
• Median overall survival (mOS) for repeat dose GBM patients is 17.2+ months, exceeding the SOC of 13.2 months.
• No dose-limiting toxicities (DLTs), CRS, or neurotoxicity were reported in the GBM trials.
• The company hosted its R&D Day on May 21, 2026, to discuss its TCE platform and GBM program.
• IN8bio had $21.9 million in cash as of March 31, 2026.
• Net loss for the quarter was $5.1 million, or $0.26 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to strong clinical data in GBM and advancements in the TCE platform, despite the ongoing net loss typical for clinical-stage biotechs.

Positives

• Demonstrated a 97% improvement in progression-free survival (PFS) for repeat dose GBM patients compared to standard-of-care (SOC).
• Achieved a median overall survival (mOS) of 17.2+ months in repeat dose GBM patients, surpassing the SOC of 13.2 months.
• Reported no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), or neurotoxicity in GBM clinical trials.
• Preclinical data for INB-619 showed complete B cell depletion, robust T cell expansion, and minimal CRS-associated cytokine release.
• Increased cash position to $21.9 million as of March 31, 2026, from $11.9 million in the prior year period.
• Reduced R&D expenses to $2.6 million from $3.0 million in the prior year period, potentially indicating improved efficiency or shifted trial activity.

Negatives

• Reported a net loss of $5.1 million for the first quarter of 2026.
• The company's cash position decreased from $27.1 million at the end of 2025 to $21.9 million at the end of Q1 2026.
• Weighted-average shares outstanding increased significantly from approximately 2.6 million in Q1 2025 to 19.5 million in Q1 2026, impacting per-share metrics.

Risks

• The company may not be able to raise additional capital and could be forced to delay, reduce, or terminate development programs.
• The company's ability to continue as a going concern is subject to raising additional capital.
• Uncertainties exist in the initiation and completion of preclinical studies and clinical trials.
• Outcomes of preclinical studies may not be predictive of clinical trial results.
• Clinical trials may be delayed and may not have satisfactory outcomes.
• Potential adverse effects may arise from testing or use of product candidates.
• Regulatory approvals to conduct trials or market products are uncertain.
• Reliance on third parties, including licensors and clinical research organizations.

Future Outlook

IN8bio anticipates guidance from the FDA on potential accelerated regulatory pathways for its GBM program in the second half of 2026. The company expects to publish Phase 1 INB-200 clinical data in a peer-reviewed journal, present additional GBM clinical updates including updated mOS data at ASCO 2026, and provide initial TCE preclinical animal data and additional IND-enabling data for INB-619 in the second half of 2026. Completion of INB-100 patient dosing and presentation of long-term follow-up results are expected in late 2026.

Management Comments

• "In the first quarter of 2026, we continued to advance our next-generation TCE platform and clinical programs," said William Ho, Chief Executive Officer and co-founder of IN8bio.
• "Our encouraging GBM data positions us to engage the FDA on potential regulatory pathways forward, and we expect to deliver meaningful preclinical, regulatory and clinical milestones across our pipeline this year."
• "As industry interest in novel TCEs accelerates, our next-generation platform is designed to address the key challenges in TCE development."
• "We believe IN8bio is well positioned to create meaningful value for patients and shareholders in 2026 and beyond."
• "We look forward to sharing further updates across our programs at our upcoming R&D Day in New York City on May 21, 2026."

Industry Context

StockSavvy.ai notes that IN8bio's focus on gamma-delta T cell therapies and T cell engagers aligns with a growing trend in the biopharmaceutical industry towards developing more targeted and potentially less toxic cancer treatments. The company's progress in glioblastoma, a notoriously difficult-to-treat cancer, and its development of novel TCEs address significant unmet medical needs.

Comparison to Industry Standards

• The reported 97% improvement in progression-free survival (PFS) for newly diagnosed glioblastoma (GBM) patients in IN8bio's trials significantly surpasses historical benchmarks for standard-of-care (SOC) treatments, which typically show PFS in the range of 6-7 months.
• The median overall survival (mOS) of 17.2+ months observed in IN8bio's repeat-dose GBM patients also appears to exceed the typical mOS for SOC, which is often around 13-14 months.
• The absence of dose-limiting toxicities (DLTs), CRS, and neurotoxicity in IN8bio's trials is a positive differentiator compared to some other advanced cell therapies and immunotherapies that can present significant safety challenges.
• The development of T cell engagers (TCEs) like INB-619 is a competitive area, with companies like Amgen (with Blinatumomab) and Regeneron making strides in CD3-based TCEs. IN8bio's approach aims to differentiate by potentially reducing CRS and widening the therapeutic window.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future value creation if clinical and regulatory milestones are met, but also risk of dilution from equity incentive plans and ongoing capital needs.
• Patients: Potential for improved treatment outcomes in GBM and other cancers/autoimmune diseases with novel T cell therapies and TCEs.
• Employees: Continued incentive through the approved equity plan.
• Creditors: The company's cash position and net loss indicate a need for continued financing, impacting creditor confidence.

Next Steps

• Engage the FDA on potential regulatory pathways for the GBM program in 2H26.
• Present updated mOS data at the ASCO 2026 Annual Meeting on June 1, 2026.
• Host R&D Day on May 21, 2026, to discuss TCE platform and GBM program.
• Publish Phase 1 INB-200 clinical data in a peer-reviewed journal.
• Provide initial TCE preclinical animal data and additional IND-enabling data for INB-619 in 2H26.
• Complete INB-100 patient dosing and present long-term follow-up results in late 2026.

Key Dates

Recommendation

The strong clinical data in GBM and advancements in the TCE platform are positive indicators. However, the company's ongoing net losses, significant increase in share count, and reliance on future capital raises warrant a cautious 'hold' recommendation until further de-risking events, such as FDA guidance or successful capital raises, occur.

Keywords

IN8bio, T cell therapy, Glioblastoma, T cell engager, Biopharmaceutical, Clinical trial, Financial results, R&D